BioNexus Gene Lab (BGLC) Gross Profit (2018 - 2026)

BioNexus Gene Lab has disclosed Gross Profit across 9 years of filings, most recently posting -$790.0 for Q1 2026.

• Gross Profit for Q1 2026 came in at -$790.0, down 100.23% year-over-year; the trailing twelve-month figure through Mar 2026 was $740934.0 (down 41.57% YoY), and the FY2025 annual result was $1.1 million, down 15.84% from the prior year.
• Gross Profit came in at -$790.0 for Q1 2026 at BioNexus Gene Lab, up from -$3983.0 in the prior quarter.
• In the past five years, Gross Profit ranged from a high of $377685.0 in Q3 2025 to a low of -$3983.0 in Q4 2025.
• The 5-year median for Gross Profit is $339226.0 (2022), against an average of $291910.3.
• Across the five-year window, Gross Profit climbed 28.69% in 2023 and slumped 101.29% in 2025, its largest moves.
• BioNexus Gene Lab's Gross Profit stood at $339226.0 in 2022, then fell by 21.42% to $266555.0 in 2023, then rose by 16.01% to $309234.0 in 2024, then plunged by 101.29% to -$3983.0 in 2025, then surged by 80.17% to -$790.0 in 2026.
• The last three Gross Profit figures came in at -$790.0 (Q1 2026), -$3983.0 (Q4 2025), and $377685.0 (Q3 2025), per Business Quant data.